Alto Neuroscience, Inc. (ANRO) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.10
↑+101% vs avg
5yr avg: 2.04
30Y Low0.7·High3.4
ROE
↑
-41.8%
↓+57% vs avg
5yr avg: -97.9%
30Y Low-154%·High-42%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANRO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alto Neuroscience, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $753M | $514M | $104M | — | — | — |
| Enterprise Value | $581M | $341M | $-47218540 | — | — | — |
| P/E Ratio → | -9.80 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 4.10 | 3.40 | 0.69 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ANRO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
ANRO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -41.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 31.0% |
| Operating Margin | — | — | — | — | — | -5741.0% |
| Net Profit Margin | — | — | — | — | — | -4374.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -41.8% | -41.8% | -154.0% | — | — | — |
| ROA | -34.9% | -34.9% | -46.5% | -52.8% | -69.6% | -31.9% |
| ROIC | — | — | — | — | — | — |
| ROCE | -38.9% | -38.9% | -55.2% | -59.9% | -80.8% | -44.7% |
ANRO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $176M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.14 | -1.00 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -26.88 | -26.88 | -45.68 | -25.50 | — | — |
Net cash position: cash ($176M) exceeds total debt ($4M)
ANRO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alto Neuroscience, Inc.'s current ratio of 15.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 15.22x to 15.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 15.69 | 15.69 | 16.92 | 15.22 | 8.85 | 15.30 |
| Quick Ratio | 15.69 | 15.69 | 16.92 | 15.22 | 8.85 | 15.30 |
| Cash Ratio | 15.58 | 15.58 | 16.81 | 14.71 | 8.69 | 14.20 |
| Asset Turnover | — | — | — | — | — | 0.01 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 3029.50 |
ANRO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alto Neuroscience, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $29M | $25M | $27M | $26M | $26M |
Peer Comparison
Compare ANRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANROYou | $753M | -9.8 | — | — | — | — | -41.8% | — | — |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AXSM | $13B | -69.3 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INTR | $3B | 10.2 | 16.4 | 4.3 | 42.4% | 10.9% | 13.2% | 3.9% | 15.4 |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 ILMN | $24B | 29.5 | 22.6 | 26.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $174B | 26.5 | 18.9 | 27.7 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
What if you invested $1,000 in ANRO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ANRO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ANRO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationANRO vs SAVA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Cassava Sciences, Inc..
Compare NowANRO — Frequently Asked Questions
Quick answers to the most common questions about buying ANRO stock.
What is Alto Neuroscience, Inc.'s P/E ratio?
Alto Neuroscience, Inc.'s current P/E ratio is -9.8x. This places it at the 50th percentile of its historical range.
What is Alto Neuroscience, Inc.'s ROE?
Alto Neuroscience, Inc.'s return on equity (ROE) is -41.8%. The historical average is -97.9%.
Is ANRO stock overvalued?
Based on historical data, Alto Neuroscience, Inc. is trading at a P/E of -9.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.